Saltar al contenido
MilliporeSigma
Todas las fotos(1)

Documentos

SML3054

Sigma-Aldrich

CHIR124

≥98% (HPLC)

Sinónimos:

4-[((3S)-1-Azabicyclo[2.2.2]oct-3-yl)amino]-3-(1H-benzimidazol-2-yl)-6-chloroquinolin-2(1H)-one, 4-[(3S)-1-Azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-yl)-6-chloro-2(1H)-quinolinone, CHIR 124, CHIR-124, f 4-[((3S)-
quinuclidin-3-yl)amino]-3-benzimidazol-2-yl-6-chloro-hydroquinolin-2- one

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C23H22ClN5O
Número de CAS:
405168-58-3
Peso molecular:
419.91
MDL number:
MFCD14636453
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

O=C1NC2=CC=C(Cl)C=C2C(N[C@@H]3CN4CCC3CC4)=C1C5=NC6=C(C=CC=C6)N5

InChI

1S/C23H22ClN5O/c24-14-5-6-16-15(11-14)21(25-19-12-29-9-7-13(19)8-10-29)20(23(30)28-16)22-26-17-3-1-2-4-18(17)27-22/h1-6,11,13,19H,7-10,12H2,(H,26,27)(H2,25,28,30)/t19-/m1/s1

InChI key

MOVBBVMDHIRCTG-LJQANCHMSA-N

Biochem/physiol Actions

CHIR124 is a potent and selective inhibitor of checkpoint kinase 1 (Chk1)( IC50 = 0.3 nM) that produces G2-M abrogation which induces chemosensitisation. It also inhibits PDGFR and FLT3 (IC50 = 6.6 nM and 5.8 nM respectively). CHIR-124 inhibits Pgp activity in multidrug-resistant cell lines KB-V1 and A2780-Pac-Res.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Archie N Tse et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 13(2 Pt 1), 591-602 (2007-01-27)
Chk1 kinase is a critical regulator of both S and G(2)-M phase cell cycle checkpoints in response to DNA damage. This study aimed to evaluate the biochemical, cellular, and antitumor effects of a novel Chk1 inhibitor, CHIR124. CHIR-124 was evaluated
Rida Zahra et al.
PloS one, 15(6), e0233993-e0233993 (2020-06-03)
Multidrug resistance (MDR) to chemotherapeutic drugs remains one of the major impediments to the treatment of cancer. Discovery and development of drugs that can prevent and reverse the acquisition of multidrug resistance constitute a foremost challenge in cancer therapeutics. In
Siang-Boon Koh et al.
Cancer research, 78(11), 3054-3066 (2018-05-08)
Combination of cytotoxic therapy with emerging DNA damage response inhibitors (DDRi) has been limited by tolerability issues. However, the goal of most combination trials has been to administer DDRi with standard-of-care doses of chemotherapy. We hypothesized that mechanism-guided treatment scheduling

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico